PDCD1 and small cell lung carcinoma: A supplementary phase I clinical trial (NCT02660034) was conducted to evaluate the safety of combining the PARP inhibitor Pamiparib (also known as BGB290, manufactured by BeiGene, Beijing, China and Cambridge, MA, United States), Basel, Switzerland) with the anti-PD-1 antibody Tislelizumab (also known as BGB-A317) in 49 patients with recurrent SCLC [85].